U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20FNO3
Molecular Weight 331.3784
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CTP-347

SMILES

c1cc(ccc1[C@]2([H])CCNC[C@@]2([H])COc3ccc4c(c3)OC([H])([H])O4)F

InChI

InChIKey=AHOUBRCZNHFOSL-SVLNYFRSSA-N
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1/i12D2

HIDE SMILES / InChI

Molecular Formula C19H20FNO3
Molecular Weight 331.3784
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Jun 26 16:29:38 UTC 2021
Edited
by admin
on Sat Jun 26 16:29:38 UTC 2021
Record UNII
KP3VT00O7V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CTP-347
Common Name English
PIPERIDINE, 3-((1,3-BENZODIOXOL-5-YL-2,2-D2-OXY)METHYL)-4-(4-FLUOROPHENYL)-, (3S,4R)-
Common Name English
D2-PAROXETINE
Common Name English
Code System Code Type Description
CAS
923932-43-8
Created by admin on Sat Jun 26 16:29:38 UTC 2021 , Edited by admin on Sat Jun 26 16:29:38 UTC 2021
PRIMARY
PUBCHEM
58946140
Created by admin on Sat Jun 26 16:29:38 UTC 2021 , Edited by admin on Sat Jun 26 16:29:38 UTC 2021
PRIMARY
FDA UNII
KP3VT00O7V
Created by admin on Sat Jun 26 16:29:38 UTC 2021 , Edited by admin on Sat Jun 26 16:29:38 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
NON-LABELED -> LABELED
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MAXIMUM TOLERATED DOSE TOXICITY SOCIAL PHOBIA: 37.5 mg/day (CONTROLLED-RELEASE TABLET)

OBSESSIVE-COMPULSIVE DISORDER: 60 mg/day (FDA DOSAGE) (IMMEDIATE-RELEASE TABLET AND SUSPENSION)

OBSESSIVE-COMPULSIVE DISORDER: 60 -100 mg/day (GUIDELINE DOSAGE) (RAPID METABOLIZERS OR THOSE WITH INADEQUATE RESPONSE AFTER 8 WEEKS)

PANIC DISORDER: 60 mg/day (IMMEDIATE-RELEASE TABLET AND SUSPENSION)

MAJOR DEPRESSIVE DISORDER: 62.5 mg/day (CONTROLLED-RELEASE TABLET)

PANIC DISORDER: 75 mg/day (CONTROLLED-RELEASE TABLET)

Route of Elimination PHARMACOKINETIC EXCRETED UNCHANGED

Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
PROTEIN BINDING PHARMACOKINETIC
Tmax PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC EXCRETED UNCHANGED